List view / Grid view
25 February 2014 | By The European Medicines Agency
Over the past twelve months, a total of 12 medicines for the treatment of rare diseases were recommended for marketing authorisation by the European Medicines Agency’s Committee for Medicinal Products for Human Use...
25 February 2014 | By Novartis
A strong majority of Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting...
25 February 2014 | By Daiichi Sankyo Company
Daiichi Sankyo has announced that its consolidated subsidiary, Ranbaxy Laboratories, will temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India.
24 February 2014 | By Pfizer
Pfizer Inc. announced that the Community-Acquired Pneumonia Immunization Trial in Adults achieved its primary clinical objective and both secondary clinical objectives...
24 February 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has granted its investigational DCV Dual Regimen Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection...
24 February 2014 | By Novartis
Novartis announced that its meningococcal serogroup B vaccine, Bexsero®, will be used as part of a vaccination program at the University of California Santa Barbara and will end on March 7...
21 February 2014 | By The European Medicines Agency
The European Medicines Agency has concluded its review of Protelos/Osseor and has recommended further restricting the use of the medicine to patients who cannot be treated with other medicines approved for osteoporosis...
21 February 2014 | By Roche
New automated CINtec PLUS test improves the detection of cervical pre-cancer...
21 February 2014 | By Teva Pharmaceutical Industries Ltd
Innovative new inhaler for asthma and COPD patients
21 February 2014 | By Novartis
Lucentis® (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: the treatment of patients with diabetic macular edema, a leading cause of vision loss among patients with diabetes...
21 February 2014 | By Merck
MSD has announced full study findings from a pan-European observational study that showed the majority of moderate-to-severe ulcerative colitis patients who were treated with conventional therapies failed to achieve well-controlled disease status...
21 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium under the proposed brand name Incruse®...
20 February 2014 | By Merck
Merck announced that the Biologics License Application for V503...
20 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol under the proposed brand name Anoro®...
19 February 2014 | By Novartis
Novartis announced that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment...
